Meeting
2023 ASCO Genitourinary Cancers Symposium
Treatment patterns, indicators of receiving systemic treatment, and clinical outcomes in metastatic urothelial carcinoma: A retrospective analysis of real-world data in Germany.
Authors
Guenter Niegisch
University Hospital and Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany
Guenter Niegisch , Marc-Oliver Grimm , Fraence Hardtstock , Julia Krieger , Alexandra Starry , Ulrike Osowski , Silke Guenther , Barthold Deiters , Ulf Maywald , Thomas Wilke , Mairead Kearney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 464)
DOI
10.1200/JCO.2023.41.6_suppl.464
Abstract #
464
Poster Bd #
H5
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Real-world treatment patterns and clinical outcomes among patients with metastatic urothelial carcinoma.
First Author: Daniel M. Geynisman
Poster
2023 ASCO Quality Care Symposium
Real-world overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line (1L) systemic therapy (tx): Results from IMPACT UC II.
First Author: Mehmet Asim Bilen
Poster
2023 ASCO Annual Meeting
Real-world study of treatment patterns and clinical outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) post-approval of immunotherapy in the community oncology setting.
First Author: Alexander I. Spira
Poster
2020 Genitourinary Cancers Symposium
Real-world outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) who received first- or second-line immunotherapies (IO) in the United States (US).
First Author: Marley Boyd